1-3 of 3
Stefan Zahn
Close
Sort by
Journal Articles

Preclinical characterization of 1-7F9, a novel human anti–KIR receptor therapeutic antibody that augments natural killer–mediated killing of tumor cells

Francois Romagné, Pascale André, Pieter Spee, Stefan Zahn, Nicolas Anfossi, Laurent Gauthier, Marusca Capanni, Loredana Ruggeri, Don M. Benson, Jr, Bradley W. Blaser, Mariella Della Chiesa, Alessandro Moretta, Eric Vivier, Michael A. Caligiuri, Andrea Velardi, Nicolai Wagtmann
Journal: Blood
Blood (2009) 114 (13): 2667–2677.
https://doi.org/10.1182/blood-2009-02-206532
Published: 2009
Includes: Supplemental data
Journal Articles

Anti-KIR (1-7F9): A Fully Human Monoclonal Antibody (mAb) That Blocks KIR2DL1, −2 and −3, Promoting Natural Killer (NK) Cell-Mediated Lysis of Tumor Cells In Vitro and In Vivo.

Nicolai Wagtmann, PhD, Pascale Andre, PhD, Stefan Zahn, PhD, Pieter Spee, PhD, Nicolas Anfossi, PhD, Laurent Gauthier, PhD, Bradley W. Blaser, PhD, Michael A. Caligiuri, MD, Marusca Capanni, Loredana Ruggeri, PhD, Andrea Velardi, MD, Francois Romagne, PhD
Journal: Blood
Blood (2007) 110 (11): 582.
https://doi.org/10.1182/blood.V110.11.582.582
Published: 2007
Journal Articles

The CXC-Chemokine Neutrophil-Activating Peptide-2 Induces Two Distinct Optima of Neutrophil Chemotaxis by Differential Interaction With Interleukin-8 Receptors CXCR-1 and CXCR-2

Andreas Ludwig, Frank Petersen, Stefan Zahn, Otto Götze, Jens-Michael Schröder, Hans-Dieter Flad, Ernst Brandt
Journal: Blood
Blood (1997) 90 (11): 4588–4597.
https://doi.org/10.1182/blood.V90.11.4588
Published: 1997